Atomo Diagnostics Ltd (ASX:AT1)
A$ 0.017 -0.0020 (-10.53%) Market Cap: 15.34 Mil Enterprise Value: 12.33 Mil PE Ratio: 0 PB Ratio: 2.13 GF Score: 0/100

Half Year 2026 Atomo Diagnostics Ltd Earnings Call Transcript

Jan 27, 2026 / 03:00 AM GMT
Release Date Price: A$0.037 (-5.13%)

Key Points

Positve
  • Atomo Diagnostics Ltd (ASX:AT1) reported a significant increase in revenue, reaching $1.5 million, more than double the previous quarter.
  • The company has secured a substantial order for its HIV self-test product in Africa, supported by the Global Fund.
  • Atomo Diagnostics Ltd (ASX:AT1) has signed a valuable strategic partnership with Burnett for the development of novel rapid test assays.
  • The company has seen a 170% increase in its share price since the start of the fiscal year, indicating strong market momentum.
  • Atomo Diagnostics Ltd (ASX:AT1) has successfully reduced its cash burn, with net cash from operating activities being positive for the quarter.
Negative
  • The company continues to face ongoing losses, although they have been reducing over time.
  • There is uncertainty regarding the timing of FDA clear waiver decisions for the FebriDX product, as Atomo Diagnostics Ltd (ASX:AT1) is not directly handling the FDA process.
  • The company is still in the process of finalizing regulatory and clinical planning for its syphilis test, with trials expected to start in the next three to six months.
  • Atomo Diagnostics Ltd (ASX:AT1) needs to optimize its swab test and Florrie device for specific applications, which requires finding partners to fund commercialization.
  • The company is reliant on grants and partnerships to fund product development, which may limit its ability to independently bring products to market.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AT1.AX - Atomo Diagnostics Ltd
Half Year 2026 Atomo Diagnostics Ltd Earnings Call
Jan 28, 2026 / 03:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified Company Representative Atomo Diagnostics ltd [1]
--------------------------------------------------------------------------------
Q2 FY'26 quarterly report. Today we will be running through a presentation style format, and I will be talking a little bit about the quarterly highlights. We will be jumping into some of those matters in a little bit more detail. We do have a number of questions, there will be a Q&A section at the end.

However, we have tried where appropriate to address some of those questions on the deck and with the commentary. So, if those questions are dealt with, we'll not be dealing with them again at the end of the presentation in the Q&A slide.

So in terms of activity quarterly summary, obviously continuing to see growth in our OEM Pascal business driven primarily
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot